Reprogramming immune cells
restoring lives
Resetting the energy metabolism
of dysfunctional immune cells
to conquer disease

A breakthrough approach

for a broad range of immune-mediated
and mitochondrial diseases

Tranquis Therapeutics, a trailblazing clinical-stage biopharmaceutical company, is developing a portfolio of small molecule drugs capable of reprogramming dysfunctional myeloid immune cells to restore normal cell homeostasis and function.

Our therapeutic candidates can “switch” dysfunctional microglia and monocytes back to a more functional state by targeting master regulators of cell energy metabolism, such as PGC1α. We have the potential to revolutionize the management of an entire range of CNS and non-CNS indications by modifying disease—starting with ALS—to improve millions of lives throughout the world.

Smart science

The expertise, innovation and capabilities to advance the treatment of immune-mediated and mitochondrial diseases

Promising pipeline

A portfolio of drug candidates in clinical and pre-clinical development—ready to transform a range of diseases

Compelling careers

Join our exciting, collaborative and passionate
workplace—driven to make a difference in patients’ lives